Welcome to MOLOGEN AG

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

DR. MARIOLA SÖHNGEN CEO MOLOGEN AG

• Next Level corporate strategy being implemented according to plan • Progress made in ongoing clinical trials and preparations underway for new studies in various indications • A licensing and development cooperation contract signed with ONCOLOGIE; first payment received • Additional capital measures successfully completed • Confirmation of... [more]

Today, the Management Board and the Supervisory Board of MOLOGEN AG have decided to propose to the Annual General Meeting planned for 8 June 2018 to resolve on a reduction of the existing share capital by €30,149,148 to an amount of €7,537,287. The capital reduction shall be effected in accordance with the provisions on the simplified capital... [more]

Annual Report 2017

Download pdf

Quarterly Statement as at 31 March 2018

Download pdf